EXAS
EXACT Sciences Corporation
NASDAQ: EXAS · HEALTHCARE · DIAGNOSTICS & RESEARCH
$104.91
+0.00% today
Updated 2026-03-24
Market cap
$20.03B
P/E ratio
—
P/S ratio
6.17x
EPS (TTM)
$-1.10
Dividend yield
—
52W range
$39 – $1,878
Volume
2.7M
EXACT Sciences Corporation (EXAS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-6.40%
Operating margin
-9.28%
ROE
-8.66%
ROA
-1.59%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $4.75M | $-12.91M | 82.97% | -298.25% | -271.89% |
| 2007 | $2.94M | $-11.96M | 59.59% | -437.72% | -407.46% |
| 2008 | $-867000.00 | $-9.74M | 100.12% | 1,150.29% | 1,123.53% |
| 2009 | $4.76M | $-9.09M | 99.58% | -193.53% | -191.03% |
| 2010 | $5.34M | $-11.56M | 99.55% | -221.29% | -216.24% |
| 2011 | $4.16M | $-28.68M | 99.42% | -692.36% | -688.81% |
| 2012 | $4.14M | $-52.42M | 100.00% | -1,270.32% | -1,264.99% |
| 2013 | $4.14M | $-46.51M | 100.00% | -1,128.40% | -1,122.44% |
| 2014 | $1.80M | $-100.05M | -140.55% | -5,591.71% | -5,564.40% |
| 2015 | $39.44M | $-157.80M | 37.87% | -403.35% | -400.14% |
| 2016 | $99.38M | $-167.21M | 54.52% | -170.08% | -168.26% |
| 2017 | $265.99M | $-114.40M | 70.23% | -44.48% | -43.01% |
| 2018 | $454.46M | $-175.15M | 74.04% | -35.09% | -38.54% |
| 2019 | $876.29M | $-213.09M | 75.27% | -26.68% | -24.32% |
| 2020 | $1.49B | $-823.61M | 76.24% | -51.48% | -55.22% |
| 2021 | $1.77B | $-595.63M | 74.04% | -48.42% | -33.71% |
| 2022 | $2.08B | $-623.51M | 68.27% | -28.48% | -29.91% |
| 2023 | $2.50B | $-204.15M | 70.49% | -8.60% | -8.17% |
| 2024 | $2.76B | $-1.03B | 69.55% | -38.01% | -37.29% |
| 2025 | $3.25B | $-207.95M | 69.69% | -3.05% | -6.40% |